Clincial Trials KOL Commentaries - Clinical Trials KOL Commentary Primary and novel androgen deprivation therapy for prostate cancer: balancing efficacy and potential toxicitiesMary-Ellen Taplin VIEW MORE Case study Case Study (2019-2023): Changing treatmentsMary-Ellen Taplin VIEW MORE Case study mHSPC: A Clinical Case StudyJordan Ciuro & Atish Choudhury VIEW MORE KOL Commentary Updates in mHSPC ASCO Genitourinary Symposium 2023Atish Choudhury & Jordan Ciuro VIEW MORE KOL Commentary Novel therapeutic strategies that are helping HCPs manage patients and improving outcomesWilliam Oh VIEW MORE Infographics - Clinical Trials Biomarkers for the Prediction of Disease Progression, Prognosis, and Treatment Response of Metastatic Prostate Cancer VIEW INFOGRAPHIC Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer VIEW INFOGRAPHIC Articles - Clinical Trials Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial READ MORE Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer READ MORE Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer READ MORE Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk READ MORE Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol READ MORE Toxicity and Efficacy of Concurrent Androgen Deprivation Therapy, Pelvic Radiotherapy, and Radium-223 in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer READ MORE Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study READ MORE Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer READ MORE Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial READ MORE Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial READ MORE Facebook Twitter Linkedin
